Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis

Chest

Volumn 137, Issue 5, 2010, Pages 1157-1163

  Keating, Claire L ^a   Liu, Xinhua ^b   DiMango, Emily A ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b Mailman School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; DIAGNOSTIC TEST; FEMALE; FORCED EXPIRATORY VOLUME; GENE MUTATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; STATISTICS; UNITED STATES;

EID: 77951860169     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-1352     Document Type: Article

References (29)

1. Cystic Fibrosis Foundation Patient Registry 2006 Annual Report. Bethesda, MD:Cystic Fibrosis Foundation; 2008.
2. Cystic Fibrosis Foundation Patient Registry 2003 Annual Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2004.
3. Widerman E, Millner L, Sexauer W, Fiel S. Health status and sociodemographic characteristics of adults receiving a cystic fibrosis diagnosis after age 18 years. Chest. 2000;118(2):427-433. (Pubitemid 30637811)
4. Gilljam M, Ellis L, Corey M, Zielenski J, Durie P, Tullis DE. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest. 2004;126(4):1215-1224. (Pubitemid 39391253)
5. McCloskey M, Redmond AO, Hill A, Elborn JS. Clinical features associated with a delayed diagnosis of cystic fibrosis. Respiration. 2000;67(4):402-407. (Pubitemid 30666002)
6. Gan KH, Geus WP, Bakker W, Lamers CB, Heijerman HG. Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years. Thorax. 1995;50(12):1301-1304.
7. Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2005;171(6):621-626.
8. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-187.
9. Choo-Kang LR, Zeitlin PL, Type I. Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy. Curr Opin Pulm Med. 2000;6(6):521-529.
10. 2007 National Patient Cystic Fibrosis Foundation Registry Report to Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2008.
11. Olivier KN, Weber DJ, Wallace RJ Jr, et al; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167(6):828-834.
12. Johansen HK, Nir M, Høiby N, Koch C, Schwartz M. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet. 1991;337(8742):631-634.
13. Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (delta F508). N Engl J Med. 1990;323(22):1517-1522.
14. Lester LA, Kraut J, Lloyd-Still J, et al. Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics. 1994;93(1):114-118. (Pubitemid 2037062)
15. The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med. 1993;329(18):1308-1313.
16. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest. 2006;130(5):1441-1447. (Pubitemid 44786738)
17. Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest. 2008;118(3):1040-1049. (Pubitemid 351364611)
18. Drumm ML, Konstan MW, Schluchter MD, et al; Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005;353(14):1443-1453.
19. Arkwright PD, Pravica V, Geraghty PJ, et al. End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med. 2003;167(3):384-389. (Pubitemid 36216420)
20. Augarten A, Kerem BS, Yahav Y, et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C→T mutation. Lancet. 1993;342(8862):25-26. (Pubitemid 23183919)
21. Mussaffi H, Prais D, Mei-Zahav M, Blau H. Cystic fibrosis mutations with widely variable phenotype: the D1152H example. Pediatr Pulmonol. 2006;41(3):250-254.
22. Feldmann D, Couderc R, Audrezet MP, et al. CFTR genotypes in patients with normal or borderline sweat chloride levels. Hum Mutat. 2003;22(4):340.
23. Boyle MP. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med. 2003;9(6):498-503. (Pubitemid 37268214)
24. Farrell PM, Rosenstein BJ, White TB, et al; Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153(2):S4-S14.
25. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol. 1995;48(8):1041-1049.
26. Levy H, Kalish LA, Cannon CL, et al. Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients. Pediatr Pulmonol. 2008;43(5):463-471. (Pubitemid 351657313)
27. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol. 1997;145(9):794-803. (Pubitemid 27188516)
28. Verma N, Bush A, Buchdahl R. Is there still a gender gap in cystic fibrosis? Chest. 2005;128(4):2824-2834. (Pubitemid 41507646)
29. Waters DL, Dorney SF, Gaskin KJ, Gruca MA, O'Halloran M, Wilcken B. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. N Engl J Med. 1990;322(5):303-308. (Pubitemid 20046333)